TP53 and central nervous system cancer: Firstly, due to the relatively small sample size and the high heterogeneity of tumours, comprehensive molecular classifications regarding common genetic alterations (e.g., IDH2, TP53, 1p/19q codeletion, TERT promoter mutation) could not be performed in the glioma cohort.